Foxpaws Fauxpas

Incredibly relevant study on immunotherapy in msi-h mCRC – Foxpaws Fauxpas

Foxpaws Fauxpas shared a post on X:

“Fantastic and incredibly relevant study on immunorx in msi-h mCRC from ACTREC-TMC, Tata Memorial Hospital, Mehak Trikha, Laboni Sarkar, Anant Ramaswamy, and Prof Vikas Ostwal

Nivo at 20 mg and 40 mg. Crazy trailblazing.

Dr Amol Akhade– thoughts.“

Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD—High Study)

Authors: Mehak Trikha, Laboni Sarkar, Aditya Dhanawat, Noorzia Syed, Himanshu Gujarathi, Manan Vora, A Sree Sivakumar Raja, Prabhat Bhargava, Anant Ramaswamy, Sarika Mandavkar, Avanish Saklani, Rajiv Kumar Kaushal, Munita Bal, Omshree Shetty, Subhash Yadav, and Vikas Ostwal.

Incredibly relevant study on immunotherapy in msi-h mCRC - Foxpaws Fauxpas

Source: Foxpaws Fauxpas/X

ACTREC-TMC Aditya Dhanawat Amol Akhade Anant Ramaswamy cancer Foxpaws Fauxpas Laboni Sarkar Mehak Trikha Omshree Shetty OncoDaily Oncology Prof Vikas Ostwal Subhash Yadav Tata Memorial Hospital Vikas Ostwal